Drug Approval | December 28, 2021
Aurobindo to manufacture and market molnupiravir
The drug will be marketed under the brand name Molnaflu
The drug will be marketed under the brand name Molnaflu
The company has developed the API in house at its R&D center in Hyderabad
This product will be manufactured at Lupin's Goa facility in India
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
FDA changes inspection classification of the facility to Voluntary Action Indicated
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Sciflix is a special Initiative by Lupin to assist future pulmonologists in staying abreast of the latest medical advances relevant to their speciality
Subscribe To Our Newsletter & Stay Updated
